
Gilead to work with Genmab on HIV targeting technology
pharmafile | August 12, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing | Genmab, Gilead, HIV, duobody
Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform to create and develop bispecific antibody candidates for a therapeutic program targeting HIV.
Gilead has made an upfront payment of $5 million to Genmab, with the potential for future development, regulatory and sales milestones of up to $277 million for the first product, with further payments for future products.
According to Genmab, the DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. DuoBody molecules are able to combine the benefits of bispecificity with the strengths of conventional antibodies, allowing them to be administered and dosed as other antibody therapeutics.
The plaform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at a standard bench, as well as on a commercial, manufacturing scale.
Jan van de Winkel, chief executive officer at Genmab, says: “We are pleased to add this agreement with Gilead to our growing list of commercial collaborations for our innovative DuoBody platform and we are particularly excited that the potential for DuoBody bispecific antibodies for treating HIV will be explored.”
Genmab indicates that the deal will not affect their 2016 financial guidance.
Sean Murray
Related Content

Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …






